May 19, 2020 / 03:30PM GMT
Randall S. Stanicky - RBC Capital Markets, Research Division - MD of Global Equity Research & Lead Analyst
Great. Thanks, everybody, for joining us for our next virtual fireside chat here. We're kicking things off again with our next company. I'm Randall Stanicky, the pharmaceuticals analyst here at RBC Capital Markets.
And next up, we have Pfizer. The stock has proven resilient in the current pandemic. It's one of the names that we've been highlighting as defensive and wanting to own in this environment. And so with us to chat on the company, current dynamics and outlook here, Senior Vice President of Investor Relations, Chuck Triano.
And so Chuck, first, I just want to say thanks for joining us. It's great to have Pfizer at our conference. So thank you for that.
Questions and Answers:
Randall S. Stanicky - RBC Capital Markets, Research Division - MD of Global Equity Research & Lead AnalystAnd then to start off, let's jump into DMD and the market opportunity. This was something that you guys sounded pretty excited about on
Trustpilot
